Antimicrobial resistance to medicinal products for human use and veterinary medicinal products is a growing health problem in the European Union and worldwide. The use of antimicrobial medicinal products that are used in animals may accelerate the emergence and spread of resistant micro-organisms and may compromise the effective use of the already limited number of existing antimicrobial medicinal products to treat human infections. Strengthening the prudent use of antimicrobial medicinal products to in the European Union has resulted in an increasing interest in the use of autogenous vaccines.
WHAT ARE AUTOGENOUS VACCINES FOR VETERINARY USE?
Autogenous vaccine for veterinary use is a vaccine prepared using microorganisms which have been isolated from the same infected animal to which it is then administered.
Today, global manufacturers of veterinary medicinal products provide autogenous vaccines for livestock farms around the world.
BENEFITS OF AUTOGENOUS VACCINES
The pluses of autogenous vaccines
Prevent rather than cure:
- limit disease occurrence;
- deal with multi-resistant bacteria.
This is the function of every vaccine; the development of bacterial resistance has abolished the option of antibiotic treatment.
Contribute to public health:
- reduce excretion of the microbial toxins that cause infection;
- limit the use of anti-infective agents;
The food-processing industry has a duty to protect consumer health.
Provide solutions where there are no vaccines:
- vaccinate as a matter of urgency in the case of emerging diseases;
- propose solutions for diseases described as “minor” and for species designated as “secondary”.
The time and cost involved in developing a commercial vaccine are sometimes incompatible with the demands of those working on the ground and of the target markets.
Obtain specific immunity:
- fight against vaccination failure.
Antigenic variability within the same bacterial species, within the same serotype even, is such that total protection is often unpredictable when the vaccine antigen differs from the aggressor.
Reduce the costs of production:
- limit the number of vaccine interventions by combining several valencies;
- develop innovative pharmaceutical forms that reduce human interventions.
The cost of handling the animals and the resulting inconveniences for those involved as well as the stress caused to the animals themselves demand a commitment to simplify plans for prophylaxis. The number of injections can be reduced by combining several valencies. Excellent protection can be obtained in some cases with a single administration by developing high-performance adjuvants. Autogenous vaccines adapted to oral administration can be used in certain indications [1]...
Full text GMPnews.Net